Article thumbnail

Ethical issues in naturalistic versus controlled trials

By Hanfried Helmchen

Abstract

Ethical core issues in research with human subjects are related to informed consent and risk-benefit assessment. This is valid for all types of studies. However, there has been much greater focus of ethical considerations on controlled clinical trials than on naturalistic trials, probably because the former are interventional in nature and may have unknown and perhaps severe somatic risks, whereas naturalistic studies seem not to intervene but only to observe, and therefore are assumed to have fewer or almost no risks. However, there are also ethical implications in naturalistic trials, although their weight is differently accentuated, more with potential, more with potential psychological burdens of the observational procedures and more with potential physical risks in interventional trials. This will be elaborated with examples of placebo-controlled trials and of incidental findings in screenings, of marketing influences on observational studies, and of psychological burdens by survey interviews. The ethical implications wilt be analyzed within a more general framework, Finally, recommendations will be offered

Topics: Clinical Research
Publisher: Les Laboratoires Servier
OAI identifier: oai:pubmedcentral.nih.gov:3182002
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Antidepressant drug effects and depression severity: a patient-level meta-analysis.
  2. Assessing decisional capacity for clinical research or treatment: a review of instruments.
  3. Assessing research risks systematically: the net risks test.
  4. (2002). Biomedizinische Forschung mit einwilligungsunfähigen Erwachsenen. In: Taupitz
  5. Brain imaging. Incidental findings: in practice and in person.
  6. Bridging philosophical and practical implications of incidental findings in brain research.
  7. (2010). Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen vom 7.
  8. (2001). Caregivers' attitudes toward their family members' participation in Alzheimer disease research: implications for recruitment and retention. Alzheimer Dis Assoc Disord.
  9. Carers' impressions of participation in Alzheimer's disease clinical trials: what are their hopes? And is it worth it? International Psychogeriatrics.
  10. (2008). Children's and their parents' views on facing research risks for the benefit of others. Arch Pediatr Adolesc Med.
  11. Clinical research in the mentally ill. Ethical considerations.
  12. Empowering brain science with neuroethics.
  13. Ethical concerns in carrying out surveys of psychiatric morbidity.
  14. Ethical guidelines in psychiatric research.
  15. Ethical issues in neuroimaging health research.
  16. (1990). Ethical issues policy statement on Huntington's disease molecular genetics predictive test. International Huntington Association. World Federation of Neurology.
  17. Ethische Implikationen placebokontrollierter Prüfungen von Psychopharmaka.
  18. Evaluating the therapeutic misconception.
  19. Genetics - Ethical implications of research, diagnostics and counseling.
  20. Hartz AJ. A comparison of observational studies and randomized, controlled trials..
  21. How can research ethics committees protect patients better?
  22. In: Helmchen
  23. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis.
  24. (2008). Incidental findings: a common law approach. Account Res.
  25. (2009). Informed Consent and Medical Law.
  26. Is it possible to protect pediatric research subjects without blocking appropriate research?
  27. (2004). Making risk-benefit assessments of medical research protocols.
  28. Managing incidental findings in human subjects research: analysis and recommendations.
  29. Mental capacity in psychiatric patients: systematic review.
  30. Methodische Aspkte der Erhebungen.
  31. Non-inferiority trials are unethical because they disregard patients' interests.
  32. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression.
  33. (2003). Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci.
  34. (2009). Placeboeffekte bei Arzneimittelprüfungen von Antidepressiva: Interpretation und Bedeutung. Paper presented at: The annual congress of the German Society for Psychiatry, Psychotherapy and Clincal Neuroscience;
  35. (1997). Placebos in clinical trials of psychotropic medication.
  36. Practical approaches to incidental findings in brain imaging research.
  37. Re-evaluating the therapeutic misconception: response to Miller and Joffe. Kennedy Inst Ethics
  38. Refuting the net risks test: a response to Wendler and Miller's "Assessing research risks systematically."
  39. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology (Berl).
  40. Teaching responsible conduct of research.
  41. The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia.
  42. The ethics of placebo-controlled trials -- a middle ground.
  43. (1990). The necessity of placebo application in psychotropic drug trials.
  44. The therapeutic misconception at 25: treatment, research, and confusion. Hastings Cent Rep.
  45. The therapeutic misconception: informed consent in psychiatric research.
  46. (2004). Therapeutic misconception and the appreciation of risks in clinical trials.
  47. Unconditional compensation: reducing the costs of disagreement about compensation for research subjects.
  48. Why patients continue to participate in clinical research.